middle.news
Telix Secures FDA Nod to Expand ProstACT Phase 3 Prostate Cancer Trial
10:07am on Thursday 2nd of July, 2026 AEST
•
Healthcare
Read Story
Telix Secures FDA Nod to Expand ProstACT Phase 3 Prostate Cancer Trial
10:07am on Thursday 2nd of July, 2026 AEST
Key Points
FDA agrees on Part 2 clinical protocol and statistical plan
Part 2 involves randomized cohorts with three standard-of-care therapies
Trial continues enrolling internationally with U.S. expansion pending IND amendment
TLX591-Tx shows reduced kidney and salivary gland toxicity risks
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE